Synonyms
- A77/1726
- Arava®
- Teriflunomide
Expected Turnaround Time
4 - 9 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Collection
Serum must be separated from cells within 45 minutes of collection and transferred to a plastic transport tube. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | Unstable |
Refrigerated | Unstable |
Frozen | 6 months |
Causes for Rejection
Serum separator tube; nonfrozen sample; gel-barrier tubes
Test Details
Use
Leflunomide (Arava®) is a pyrimidine synthesis inhibitor used in the treatment of active rheumatoid arthritis. The drug is available in oral doses containing 10, 20, or 100 mg of active drug. Arava® is an isoxazole immunodulatory agent which inhibits dihydroorotate dehydrogenase (an enzyme involved in de novo pyrimidine synthesis) and has antiproliferative activity. Following oral administration, leflunomide is metabolized to an active metabolite, A77-1726 (teriflunomide), which is responsible for essentially all of its activity in vivo. Peak levels of this metabolite occurred 6 to 12 hours after dosing, with a long half-life (about two weeks).
Limitations
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
|
This test was developed and its performance characteristics determined by Lab |
|
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. |
Methodology
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
References
Brent RL. Teratogen update: Reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: Counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001 Feb; 63(2):106-112. 11241434
Physicians' Desk Reference. 66th ed. Montvale, NJ: Thompson PDR; 2012.
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf